Loading cancer entity…
Loading cancer entity…
Clinical trials
3,385 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT00530218 | Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant | completed | Phase 2 | 61 | City of Hope Medical CenterOTHER | 1 | Dec 2, 2017 |
| NCT00577512 | 2006-32 Phase II Study of Rapidly Recycled High Dose DTPACE | completed | Phase 2 | 4 | University of ArkansasOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT01524978 | A Study of Vemurafenib in Participants With BRAF V600 Mutation-Positive Cancers | completed | Phase 2 | 208 | Hoffmann-La RocheINDUSTRY | 6 | Nov 20, 2017 | clinicaltrials |
| NCT02419118 | "Monoclonal Antibodies for Treatment of Multiple Myeloma. Emphasis on the CD38 Antibody Daratumumab "(DARA) | completed | Phase 2 / Phase 3 | 4 | Vejle HospitalOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT02046915 | Phase II Multicenter, Open-label, Single Arm Clinical Study of Pomalidomide and dexamethasonE and Cyclophosphamide(PERSPECTIVE) | completed | Phase 2 | 60 | University Hospital TuebingenOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT00006184 | Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma | completed | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00899847 | Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG | completed | Phase 2 | 9 | Stanford UniversityOTHER | 1 | Oct 20, 2017 | clinicaltrials |
| NCT00081939 | UARK 2003-33, Total Therapy III | completed | Phase 2 | 303 | University of ArkansasOTHER | 1 | Oct 17, 2017 | clinicaltrials |
| NCT00054353 | Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 1 / Phase 2 | 16 | Fred Hutchinson Cancer CenterOTHER | 2 | Oct 16, 2017 | clinicaltrials |
| NCT01593410 | Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma | completed | Phase 2 | 194 | CelgeneINDUSTRY | 1 | Sep 20, 2017 | clinicaltrials |
| NCT00410605 | Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple Myeloma | completed | Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2017 | clinicaltrials |
| NCT00511238 | Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 312 | AmgenINDUSTRY | 2 | Aug 31, 2017 | clinicaltrials |
| NCT00670631 | Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment | completed | Phase 2 | 46 | Guido TricotOTHER | 0 | Aug 31, 2017 | clinicaltrials |
| NCT01866293 | Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma | completed | Phase 1 / Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 30, 2017 | clinicaltrials |
| NCT00531284 | Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma | completed | Phase 1 / Phase 2 | 184 | AmgenINDUSTRY | 1 | Aug 15, 2017 | clinicaltrials |
| NCT01339572 | Clinical And Economic Impact Of Upfront Plerixafor In Autologous Transplantation | completed | Phase 2 | 72 | University of FloridaOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00148317 | Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma | completed | Phase 2 | 38 | Weill Medical College of Cornell UniversityOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT02098109 | Non-inferiority Study of XM02 Filgrastim (Granix) and Filgrastim (Neupogen) in Combination With Plerixafor for Autologous Stem Cell Mobilization in Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | completed | Phase 2 | 100 | Washington University School of MedicineOTHER | 1 | Jul 18, 2017 | clinicaltrials |
| NCT00006244 | Melphalan, Peripheral Stem Cell Transplantation, and Interleukin-2 Followed by Interferon Alfa in Treating Patients With Advanced Multiple Myeloma | completed | Phase 2 | 36 | Fred Hutchinson Cancer CenterOTHER | 1 | Jul 12, 2017 | clinicaltrials |
| NCT01460420 | Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation(EMN-alloRIC) | completed | Phase 1 / Phase 2 | 49 | European Myeloma Network B.V.NETWORK | 4 | Jul 6, 2017 | clinicaltrials |
| NCT00222105 | A Study Evaluating Efficacy, Toxicity, Harvest Yield and Quality of Life | completed | Phase 2 | 25 | University of Kansas Medical CenterOTHER | 0 | Jul 2, 2017 | clinicaltrials |
| NCT00182663 | Thalidomide, Dexamethasone, and Clarithromycin in Treating Patients With Multiple Myeloma Previously Treated With Transplant | completed | Phase 2 | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 26, 2017 | clinicaltrials |
| NCT01775553 | Study of High Dose Carfilzomib in Multiple Myeloma Patients Who Have Progressed On Standard Dose Carfilzomib | completed | Phase 2 | 13 | Ajai ChariOTHER | 1 | Jun 21, 2017 | clinicaltrials |
| NCT00473590 | A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)(AMBER) | completed | Phase 2 | 102 | Genentech, Inc.INDUSTRY | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01158118 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00724568 | Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma(RVDD) | completed | Phase 1 / Phase 2 | 74 | University of Michigan Rogel Cancer CenterOTHER | 2 | Jun 2, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01432600 | Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide | completed | Phase 1 / Phase 2 | 80 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01313897 | UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma(NK2010-35) | completed | Phase 2 | 10 | University of ArkansasOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00619684 | Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell Transplant | completed | Phase 2 | 18 | Fred Hutchinson Cancer CenterOTHER | 1 | May 18, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT00642395 | Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT) | completed | Phase 2 | 61 | University Hospital, ToulouseOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT01206205 | Frontline Therapy in de Novo Multiple Myeloma Patients Under 65(IFM2008) | completed | Phase 2 | 31 | University Hospital, ToulouseOTHER | 1 | May 12, 2017 | clinicaltrials |
| NCT02260414 | Effects of Anticoagulant Preventive Injection in Patients With Blood Cancer(METRO B) | completed | Phase 2 | 19 | Centre Hospitalier Universitaire de Saint EtienneOTHER | 1 | May 11, 2017 | clinicaltrials |
| NCT01056276 | Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy | completed | Phase 2 | 59 | SCRI Development Innovations, LLCOTHER | 1 | May 3, 2017 | clinicaltrials |
| NCT00530816 | Phase 2 Study of Carfilzomib in Relapsed Multiple Myeloma | completed | Phase 2 | 164 | AmgenINDUSTRY | 2 | May 2, 2017 | clinicaltrials |
| NCT02072863 | A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 9 | AmgenINDUSTRY | 3 | May 2, 2017 | clinicaltrials |
| NCT01884688 | UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma | completed | Phase 2 | 3 | University of ArkansasOTHER | 1 | Apr 17, 2017 | clinicaltrials |
| NCT01351623 | Infusional Carfilzomib in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 44 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT00636909 | Nonmyeloablative Allo SCT for the Treatment of Hematologic Disorders(MINI HEME) | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 0 | Apr 6, 2017 | clinicaltrials |
| NCT01323751 | Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma(ACY-1215) | completed | Phase 1 / Phase 2 | 120 | CelgeneINDUSTRY | 1 | Apr 6, 2017 | clinicaltrials |
| NCT00259740 | Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab | completed | Phase 2 | 96 | AmgenINDUSTRY | 0 | Mar 15, 2017 | clinicaltrials |
| NCT00577642 | Bone Marker Assessment of Multiple Myeloma Patients Treated With Aminobisphosphonates | completed | Phase 2 | 29 | Massachusetts General HospitalOTHER | 1 | Mar 10, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Dec 5, 2017source: clinicaltrials